Tafamidis
FDA-approved product (capsule, oral), marketed as Vyndamax, Vyndaqel.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- AL amyloidosis
- Amyloidosis
- Cardiomyopathy
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other nervous system drugs
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tafamidis with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
NCT02791230 · start 2016-06-13
Registered record
- Registry ID
- NCT02791230
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-06-13
- Completion
- 2023-11-02
- Enrolment
- 1,733
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransthyretin (TTR) Amyloid CardiomyopathyInterventionTafamidisPhasePhase 3Registry statusCompletedA Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers
NCT02746926 · start 2016-04-29
Registered record
- Registry ID
- NCT02746926
- Conditions
- Healthy
- Interventions
- tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-04-29
- Completion
- 2016-07-15
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventiontafamidisPhasePhase 1Registry statusCompletedA Study Comparing Amounts of Tafamidis In The Blood Without Food
NCT02697864 · start 2016-04
Registered record
- Registry ID
- NCT02697864
- Conditions
- Healthy
- Interventions
- tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-04
- Completion
- 2016-06
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventiontafamidisPhasePhase 1Registry statusCompletedA Study Comparing Amounts of Tafamidis In The Blood With Or Without Food
NCT02534740 · start 2015-09
Registered record
- Registry ID
- NCT02534740
- Conditions
- Healthy
- Interventions
- tafamidis; tafamidis; tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-09
- Completion
- 2015-12
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventiontafamidis; tafamidis; tafamidisPhasePhase 1Registry statusCompletedA Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food
NCT02406560 · start 2015-04
Registered record
- Registry ID
- NCT02406560
- Conditions
- Healthy Volunteers
- Interventions
- tafamidis; tafamidis; tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2015-06
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventiontafamidis; tafamidis; tafamidisPhasePhase 1Registry statusCompletedA Bioequivalence Study Comparing Two Different Tafamidis Formulations
NCT02217813 · start 2014-10
Registered record
- Registry ID
- NCT02217813
- Conditions
- Healthy Volunteers
- Interventions
- Tafamidis; Tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-10
- Completion
- 2014-11
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionTafamidis; TafamidisPhasePhase 1Registry statusCompletedVyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
NCT02146378 · start 2014-01-10
Registered record
- Registry ID
- NCT02146378
- Conditions
- Transthyretin Familial Amyloid Polyneuropathy
- Interventions
- Vyndaqel
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-01-10
- Completion
- 2023-03-10
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransthyretin Familial Amyloid PolyneuropathyInterventionVyndaqelPhaseNot recordedRegistry statusCompletedSafety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
NCT01994889 · start 2013-12-09
Registered record
- Registry ID
- NCT01994889
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Tafamidis; Tafamidis; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-12-09
- Completion
- 2018-02-07
- Enrolment
- 441
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransthyretin (TTR) Amyloid CardiomyopathyInterventionTafamidis; Tafamidis; PlaceboPhasePhase 3Registry statusCompletedA Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)
NCT01775761 · start 2013-01
Registered record
- Registry ID
- NCT01775761
- Conditions
- TTR Cardiomyopathy
- Interventions
- Period 1; Period 2; Period 3
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2013-04
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTTR CardiomyopathyInterventionPeriod 1; Period 2; Period 3PhasePhase 1Registry statusCompletedSafety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers
NCT01655511 · start 2012-07
Registered record
- Registry ID
- NCT01655511
- Conditions
- TTR Cardiomyopathy
- Interventions
- Tafamidis; Tafamidis; Tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-07
- Completion
- 2012-09
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTTR CardiomyopathyInterventionTafamidis; Tafamidis; TafamidisPhasePhase 1Registry statusCompletedThe Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
NCT01435655 · start 2011-11
Registered record
- Registry ID
- NCT01435655
- Conditions
- Transthyretin Familial Amyloid Polyneuropathy
- Interventions
- tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2014-02
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransthyretin Familial Amyloid PolyneuropathyInterventiontafamidisPhasePhase 3Registry statusCompletedStudy Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects
NCT01369836 · start 2011-07
Registered record
- Registry ID
- NCT01369836
- Conditions
- Healthy
- Interventions
- Tafamidis meglumin; Tafamidis meglumin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-07
- Completion
- 2011-08
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionTafamidis meglumin; Tafamidis meglumin; PlaceboPhasePhase 1Registry statusCompletedPharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
NCT01358565 · start 2010-11
Registered record
- Registry ID
- NCT01358565
- Conditions
- Mild Hepatic Dysfunction; Moderate Hepatic Dysfunction
- Interventions
- Fx-1006A; Fx-1006A
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2011-04
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMild Hepatic Dysfunction; Moderate Hepatic DysfunctionInterventionFx-1006A; Fx-1006APhasePhase 1Registry statusCompletedSafety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
NCT00935012 · start 2009-09-30
Registered record
- Registry ID
- NCT00935012
- Conditions
- ATTR-CM; TTR-CM
- Interventions
- tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-09-30
- Completion
- 2019-11-20
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionATTR-CM; TTR-CMInterventiontafamidisPhasePhase 3Registry statusCompletedSafety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
NCT00925002 · start 2009-08-05
Registered record
- Registry ID
- NCT00925002
- Conditions
- ATTR-PN
- Interventions
- Tafamidis
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-08-05
- Completion
- 2020-07-08
- Enrolment
- 93
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionATTR-PNInterventionTafamidisPhasePhase 3Registry statusCompleted